Sangamo Therapeutics reported a quarterly loss of $0.08 per share, missing the Zacks Consensus Estimate for a $0.04 loss by $0.04 per share. The loss was narrower than the $0.14 per share loss a year ago, indicating year-over-year improvement despite the miss. The headline is modestly negative for sentiment but likely a limited stock mover given the narrow scope of the update.
Sangamo Therapeutics reported a quarterly loss of $0.08 per share, missing the Zacks Consensus Estimate for a $0.04 loss by $0.04 per share. The loss was narrower than the $0.14 per share loss a year ago, indicating year-over-year improvement despite the miss. The headline is modestly negative for sentiment but likely a limited stock mover given the narrow scope of the update.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly negative
Sentiment Score
-0.25
Ticker Sentiment
